Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review

The use of natural products in dermatology is increasingly being pursued due to sustainability and ecological issues, and as a possible way to improve the therapeutic outcome of chronic skin diseases, relieving the burden for both patients and healthcare systems. The legalization of cannabis by a gr...

Full description

Bibliographic Details
Main Authors: Ana M. Martins, Ana L. Gomes, Inês Vilas Boas, Joana Marto, Helena M. Ribeiro
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Pharmaceuticals
Subjects:
Online Access:https://www.mdpi.com/1424-8247/15/2/210
_version_ 1797477358118109184
author Ana M. Martins
Ana L. Gomes
Inês Vilas Boas
Joana Marto
Helena M. Ribeiro
author_facet Ana M. Martins
Ana L. Gomes
Inês Vilas Boas
Joana Marto
Helena M. Ribeiro
author_sort Ana M. Martins
collection DOAJ
description The use of natural products in dermatology is increasingly being pursued due to sustainability and ecological issues, and as a possible way to improve the therapeutic outcome of chronic skin diseases, relieving the burden for both patients and healthcare systems. The legalization of cannabis by a growing number of countries has opened the way for researching the use of cannabinoids in therapeutic topical formulations. Cannabinoids are a diverse class of pharmacologically active compounds produced by <i>Cannabis sativa</i> (phytocannabinoids) and similar molecules (endocannabinoids, synthetic cannabinoids). Humans possess an endocannabinoid system involved in the regulation of several physiological processes, which includes naturally-produced endocannabinoids, and proteins involved in their transport, synthesis and degradation. The modulation of the endocannabinoid system is a promising therapeutic target for multiple diseases, including vascular, mental and neurodegenerative disorders. However, due to the complex nature of this system and its crosstalk with other biological systems, the development of novel target drugs is an ongoing challenging task. The discovery of a skin endocannabinoid system and its role in maintaining skin homeostasis, alongside the anti-inflammatory actions of cannabinoids, has raised interest in their use for the treatment of skin inflammatory diseases, which is the focus of this review. Oral treatments are only effective at high doses, having considerable adverse effects; thus, research into plant-based or synthetic cannabinoids that can be incorporated into high-quality, safe topical products for the treatment of inflammatory skin conditions is timely. Previous studies revealed that such products are usually well tolerated and showed promising results for example in the treatment of atopic dermatitis, psoriasis, and contact dermatitis. However, further controlled human clinical trials are needed to fully unravel the potential of these compounds, and the possible side effects associated with their topical use.
first_indexed 2024-03-09T21:16:28Z
format Article
id doaj.art-f95b09090bea4837a7e3e51f5e15dff7
institution Directory Open Access Journal
issn 1424-8247
language English
last_indexed 2024-03-09T21:16:28Z
publishDate 2022-02-01
publisher MDPI AG
record_format Article
series Pharmaceuticals
spelling doaj.art-f95b09090bea4837a7e3e51f5e15dff72023-11-23T21:34:45ZengMDPI AGPharmaceuticals1424-82472022-02-0115221010.3390/ph15020210Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely ReviewAna M. Martins0Ana L. Gomes1Inês Vilas Boas2Joana Marto3Helena M. Ribeiro4Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, 1649-003 Lisbon, PortugalFaculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisbon, PortugalFaculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisbon, PortugalResearch Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, 1649-003 Lisbon, PortugalResearch Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, 1649-003 Lisbon, PortugalThe use of natural products in dermatology is increasingly being pursued due to sustainability and ecological issues, and as a possible way to improve the therapeutic outcome of chronic skin diseases, relieving the burden for both patients and healthcare systems. The legalization of cannabis by a growing number of countries has opened the way for researching the use of cannabinoids in therapeutic topical formulations. Cannabinoids are a diverse class of pharmacologically active compounds produced by <i>Cannabis sativa</i> (phytocannabinoids) and similar molecules (endocannabinoids, synthetic cannabinoids). Humans possess an endocannabinoid system involved in the regulation of several physiological processes, which includes naturally-produced endocannabinoids, and proteins involved in their transport, synthesis and degradation. The modulation of the endocannabinoid system is a promising therapeutic target for multiple diseases, including vascular, mental and neurodegenerative disorders. However, due to the complex nature of this system and its crosstalk with other biological systems, the development of novel target drugs is an ongoing challenging task. The discovery of a skin endocannabinoid system and its role in maintaining skin homeostasis, alongside the anti-inflammatory actions of cannabinoids, has raised interest in their use for the treatment of skin inflammatory diseases, which is the focus of this review. Oral treatments are only effective at high doses, having considerable adverse effects; thus, research into plant-based or synthetic cannabinoids that can be incorporated into high-quality, safe topical products for the treatment of inflammatory skin conditions is timely. Previous studies revealed that such products are usually well tolerated and showed promising results for example in the treatment of atopic dermatitis, psoriasis, and contact dermatitis. However, further controlled human clinical trials are needed to fully unravel the potential of these compounds, and the possible side effects associated with their topical use.https://www.mdpi.com/1424-8247/15/2/210<i>Cannabis sativa</i>cannabinoidsCBDTHCdermatological inflammatory diseases
spellingShingle Ana M. Martins
Ana L. Gomes
Inês Vilas Boas
Joana Marto
Helena M. Ribeiro
Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review
Pharmaceuticals
<i>Cannabis sativa</i>
cannabinoids
CBD
THC
dermatological inflammatory diseases
title Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review
title_full Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review
title_fullStr Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review
title_full_unstemmed Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review
title_short Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review
title_sort cannabis based products for the treatment of skin inflammatory diseases a timely review
topic <i>Cannabis sativa</i>
cannabinoids
CBD
THC
dermatological inflammatory diseases
url https://www.mdpi.com/1424-8247/15/2/210
work_keys_str_mv AT anammartins cannabisbasedproductsforthetreatmentofskininflammatorydiseasesatimelyreview
AT analgomes cannabisbasedproductsforthetreatmentofskininflammatorydiseasesatimelyreview
AT inesvilasboas cannabisbasedproductsforthetreatmentofskininflammatorydiseasesatimelyreview
AT joanamarto cannabisbasedproductsforthetreatmentofskininflammatorydiseasesatimelyreview
AT helenamribeiro cannabisbasedproductsforthetreatmentofskininflammatorydiseasesatimelyreview